In this article
Synovial Sarcoma Therapy and BRD9 Target Discovery
Scientists at Trinity College Dublin (TCD) have developed a new therapy that can help treat the most common rare soft tissue sarcoma affecting young people. Synovial sarcoma is a cancer that is difficult to treat due to genetic mutations. It is most commonly found in the legs or arms, and may also appear anywhere on the body.
For patients with a size of 5-10 cm, the survival rate after ten years is less than one-third. The TCD team used CRISPR gene screening technology to identify potential therapeutic targets in biology. They discovered a protein called BRD9, which can ensure the survival of synovial cells by working with the SS18-SSX protein that causes disease development.
Preclinical Drug Efficacy and Future Clinical Trials
The scientists then designed a drug that targets and degrades BRD9 protein. In experiments using mice, they found that the drugs they made could degrade the BRD9 protein and remove it from cancer cells, which could successfully prevent tumor growth. The study’s lead author, Dr. Gerard Brien, said, “It will induce cells to eliminate the proteins they depend on, causing them to die.” The team also found that the drug does not affect the cellular processes of normal cells, which causes fewer Side effects (if there are side effects). The researchers ‘next plan will be to test this new drug in patients’ , and scientists hope that these drugs will enter the clinic in the near future. The research was published in the international journal “eLIFE”.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.